Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Rhea-AI Summary

Compass Pathways (Nasdaq: CMPS), a mental health-focused biotechnology company, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company's management will deliver a presentation on March 3rd, 2025, at 1:10 pm ET.

Investors and interested parties can access a live audio webcast of the presentation through the 'Events' page in the Investors section of the Compass website. The webcast recording will remain available for 30 days after the event.

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the TD Cowen 45^th Annual Health Care Conference at 1:10 pm ET on March 3^rd, 2025.

A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

About Compass Pathways

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are living with mental health challenges and who are not helped by existing standards of care. We are pioneering the development of a new model of psilocybin treatment, in which our proprietary formulation of synthesized psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

We have commenced a phase 3 clinical program of COMP360 psilocybin treatment in TRD, the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single 25mg dose of COMP360 psilocybin with psychological support. We have completed an open label phase 2 study of COMP360 psilocybin treatment for post-traumatic stress disorder (PTSD), and we are currently conducting a phase 2 clinical study in anorexia nervosa.

Compass is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250225051779/en/

Media: Media, media@compasspathways.com

Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

Source: Compass Pathways plc

FAQ

When is Compass Pathways (CMPS) presenting at the TD Cowen Healthcare Conference 2025?

Compass Pathways will present at the TD Cowen Healthcare Conference on March 3rd, 2025, at 1:10 pm ET.

How can investors access Compass Pathways' TD Cowen conference presentation?

Investors can access the live audio webcast through the 'Events' page in the Investors section of the Compass website.

How long will the CMPS TD Cowen conference presentation replay be available?

The webcast replay will be available for 30 days following the presentation.

What is the focus of Compass Pathways' business presentation at TD Cowen?

Compass Pathways is a biotechnology company focused on accelerating patient access to evidence-based innovation in mental health.